Published in Int J Cardiol on May 04, 2013
Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med (2010) 9.19
Multipotent embryonic isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell (2006) 7.21
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
The renewal and differentiation of Isl1+ cardiovascular progenitors are controlled by a Wnt/beta-catenin pathway. Cell Stem Cell (2007) 3.54
Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation (2012) 2.32
Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet (2011) 2.10
Progression of aortic pulse wave velocity in patients with chronic kidney disease. J Clin Hypertens (Greenwich) (2013) 2.06
Platelets secrete stromal cell-derived factor 1alpha and recruit bone marrow-derived progenitor cells to arterial thrombi in vivo. J Exp Med (2006) 1.98
Mechanisms of Improved Exercise Performance under Hyperoxia. Respiration (2017) 1.94
Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med (2012) 1.93
Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol (2010) 1.93
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J (2009) 1.81
Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol (2012) 1.80
Association of ambulatory arterial stiffness index and brachial pulse pressure is restricted to dippers. J Hypertens (2008) 1.77
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol (2009) 1.73
Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. Am Heart J (2011) 1.70
Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology (2006) 1.68
Aortic pulse wave velocity predicts mortality in chronic kidney disease stages 2-4. J Hypertens (2014) 1.68
The A20 gene protects kidneys from ischaemia/reperfusion injury by suppressing pro-inflammatory activation. J Mol Med (Berl) (2008) 1.58
Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant (2009) 1.58
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J (2010) 1.56
Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension (2006) 1.53
Assessment of systolic aortic pressure and its association to all cause mortality critically depends on waveform calibration. J Hypertens (2015) 1.51
Relapsing polychondritis: An autoimmune disease with many faces. Autoimmun Rev (2010) 1.47
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial. EuroIntervention (2013) 1.47
Bare metal vs. drug-eluting stents for extracranial vertebral artery disease: a meta-analysis of nonrandomized comparative studies. J Endovasc Ther (2014) 1.43
Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J (2009) 1.43
Direct renin inhibition in a rat model of chronic allograft injury. Transplantation (2011) 1.42
Gene transfer of the pancaspase inhibitor P35 reduces myocardial infarct size and improves cardiac function. J Mol Med (Berl) (2005) 1.42
Sexual dimorphism in renal ischemia-reperfusion injury in rats: possible role of endothelin. Kidney Int (2002) 1.41
Aortic to brachial pulse pressure amplification as functional marker and predictor of renal function loss in chronic kidney disease. J Clin Hypertens (Greenwich) (2014) 1.41
Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age. Catheter Cardiovasc Interv (2013) 1.40
Correlates of poor outcome among patients with bleeding after coronary interventions. Coron Artery Dis (2014) 1.39
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents. J Am Coll Cardiol (2010) 1.38
Behavioral conditioning of immunosuppression is possible in humans. FASEB J (2002) 1.29
Citrate pharmacokinetics and calcium levels during high-flux dialysis with regional citrate anticoagulation. Nephrol Dial Transplant (2009) 1.27
Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J (2013) 1.24
Suppressed T-cell activation by IFN-gamma-induced expression of PD-L1 on renal tubular epithelial cells. Nephrol Dial Transplant (2004) 1.22
Association of hypertension with symptoms of benign prostatic hyperplasia. J Urol (2004) 1.21
Essential myosin light chain as a target for caspase-3 in failing myocardium. Proc Natl Acad Sci U S A (2002) 1.21
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med (2011) 1.20
Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart (2013) 1.19
Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. Transplantation (2005) 1.17
Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf) (2007) 1.16
Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J (2003) 1.16
Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One (2013) 1.13
Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model. J Hypertens (2012) 1.12
Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes. EuroIntervention (2014) 1.10
Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res (2011) 1.08
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol (2011) 1.07
Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients. Catheter Cardiovasc Interv (2011) 1.07
Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation (2004) 1.06
Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv (2010) 1.04
Anti-glomerular basement membrane antibody disease: a rare autoimmune disorder affecting the kidney and the lung. Autoimmun Rev (2012) 1.04
Multi-modal treatment of calciphylaxis with sodium-thiosulfate, cinacalcet and sevelamer including long-term data. Kidney Blood Press Res (2013) 1.04
Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A (2012) 1.03
Induced pluripotent stem cell-derived cardiomyocytes: a versatile tool for arrhythmia research. Circ Res (2013) 1.03
Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML). Cardiovasc Diabetol (2009) 1.02
Tumours after kidney transplantation. Curr Opin Urol (2003) 1.02
Embryonic heart progenitors and cardiogenesis. Cold Spring Harb Perspect Med (2013) 1.01
High calorie diet triggers hypothalamic angiopathy. Mol Metab (2012) 1.01
Pluripotent stem cell models of human heart disease. Cold Spring Harb Perspect Med (2013) 1.01
The effect of ischemia/reperfusion on the kidney graft. Curr Opin Organ Transplant (2014) 1.00
Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol (2008) 0.99
Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int (2008) 0.99
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl Int (2009) 0.97
Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation. J Inflamm (Lond) (2010) 0.97
Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int (2002) 0.97
Prognostic value of access and non-access sites bleeding after percutaneous coronary intervention. Circ Cardiovasc Interv (2013) 0.96
Development. ES cells to the rescue. Science (2004) 0.95
STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol (2011) 0.95
Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur J Cancer (2010) 0.93
Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney Int (2011) 0.92
Toll-like receptors 2 and 4 in renal ischemia/reperfusion injury. Pediatr Nephrol (2010) 0.92
Photons and particles emitted from cold atmospheric-pressure plasma inactivate bacteria and biomolecules independently and synergistically. J R Soc Interface (2013) 0.92
Effect of short-term high-protein compared with normal-protein diets on renal hemodynamics and associated variables in healthy young men. Am J Clin Nutr (2009) 0.92
KMnO(4)-Mediated oxidation as a continuous flow process. Org Lett (2010) 0.92
Urinary adiponectin excretion: a novel marker for vascular damage in type 2 diabetes. Diabetes (2009) 0.91
Aspects of quality of life through end-stage renal disease. Qual Life Res (2003) 0.90
Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension. Cardiovasc Res (2013) 0.90
Zotarolimus- versus everolimus-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol (2013) 0.89
[Quality of life in patients before and after kidney transplantation]. Psychother Psychosom Med Psychol (2002) 0.89
Safety of telmisartan in patients with arterial hypertension : an open-label observational study. Drug Saf (2004) 0.89
Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats. Transplantation (2005) 0.88
Renoprotective effect of erythropoietin in rats subjected to ischemia/reperfusion injury: gender differences. Surgery (2011) 0.88